Single agent checkpoint inhibitor therapy has not been effective for most gastrointestinal
solid tumors, but combination therapy with drugs targeting additional immunosuppressive …

Immunosuppression is a hallmark of pancreatic ductal adenocarcinoma (PDAC),
contributing to early metastasis and poor patient survival. Compared to the localized tumors …

Ascorbate (AscH−) functions as a versatile reducing agent. At pharmacological doses (P-
AscH−;[plasma AscH−]≥≈ 20 mM), achievable through intravenous delivery, oxidation of P …

Pancreatic cancer is characterized by an immune suppressive stromal reaction that creates
a barrier to therapy. A murine transgenic pancreatic cancer cell line that recapitulates human …

Metformin (Met) is an approved antidiabetic drug currently being explored for repurposing in
cancer treatment based on recent evidence of its apparent chemopreventive properties. Met …

Pancreatic cancer is an extremely dismal malignance. Chemotherapy has been widely
applied to treat this intractable tumor. It has exclusive tumor microenvironment (TME) …

Chemoradiation therapy is the mainstay for treatment of locally advanced, borderline
resectable pancreatic cancer. Pharmacologic ascorbate (P-AscH−, ie, intravenous infusions …

Pancreatic cancer is a devastating disease with poor prognosis in the modern era.
Inflammatory processes have emerged as key mediators of pancreatic cancer development …

Simple Summary Many signaling pathways are involved in cancer progression, and among
these pathways, the CXCL12 axis and its two receptors CXCR4 and CXCR7 are well …

The toxicity of pharmacologic ascorbate is mediated by the generation of H2O2 via the
oxidation of ascorbate. Because pancreatic cancer cells are sensitive to H2O2 generated by …